Vigabatrin (Sabril®) is a γ-aminobutyric acid-transaminase (GABA-T) inhibitor that is effective in the treatment of certain types of drug-resistant or uncontrolled epilepsy but is known to cause microscopic vacuolation (intramyelinic edema) in the brains of treated rats, mice, and dogs. The effects of high oral doses (300 mg/kg/day) of vigabatrin administered orally to Beagle dogs were studied during treatment weeks 1-12 and recovery weeks 13, 14, 16, 20, 24, and 28. Emesis, loose stools, and anorexia and 3 drug-related deaths were observed during the first 4 wk of treatment but were virtually nonexistent thereafter because of adaptation to the drug aided by food supplementation. In more sensitive areas of the brain (columns of the fomix, thalamus, and hypothalamus), microscopic quantitative differences between background vacuolation in controls and drug-related vacuolation in treated dogs could be delineated after 4 wk, generally reached highest levels of severity between 8 and 12 wk, and were reversible upon cessation of dosing. Inhibition of brain GABA-T and elevation of brain GABA were noted after 1 wk of treatment. During the course of treatment vigabatrin ranged between 4-17 nmol/ml (plasma) and 42-1,570 nmol/ml [cerebrospinal fluid (CSF)] while CSF GABA concentrations were 4-32 nmol/ml (treated dogs) and 0.1-0.6 nmol/ml (control dogs). Although the cause of vigabatrin-induced microvacuolation is unknown, the results of the study demonstrated that GABA-T inhibition with subsequent GABA elevation occurred within the first week of treatment and was followed by the onset of detectable microvacuolation several weeks later.
Arezzo JC, Schroeder CE, Litwak MS, and Steward DL (1989). Effects of vigabatrin on evoked potentials in dogs. Br. J. Clin. Pharmacol. 27: 53S-60S.
2.
Bohlen P., Huot S., and Palfreyman MG (1979). The relationship between GABA concentrations in brain and cerebrospinal fluid. Brain Res. 167: 297-305.
3.
Browne TR, Mattson RH, Penry JK, Smith DB, Treiman DM, Wilder BJ, BenMenachem E., Napoliello MJ, Sherry KM, and Szabo GK (1987). Vigabatrin for refractory complex partial seizures; multicenter single-blind study with long term follow-up. Neurology37: 184-189.
4.
Butler WH (1989). The neuropathology of vigabatrin. Epilepsia30(suppl.3): S15-S17.
5.
Butler WH, Ford GP, and Newbeme JW (1987). A study of the effects of vigabatrin on the central nervous system and retina of Sprague-Dawley and Lister-Hooded rats. Toxicol. Pathol. 15: 143-148.
6.
Cannon DJ, Butler WH, Mumford JP, and Lewis PJ (1991). Neuropathologic findings in patients receiving long-term vigabatrin therapy for chronic intractable epilepsy. J. Child Neruol. 6: 2S17-2S24.
7.
Committee on the Care and Use of Laboratory Animals (1985). Guide for the Care and Use of Laboratory Animals. NIH Publication No. 86-23. United States Department of Health and Human Services, Bethesda, MD.
8.
Fowler L. (1973). Analysis of the major amino acids of rat brain after in vivo inhibition of transaminase by ethanolamine-o-sulphate. J. Neurochem. 21: 437-440.
9.
Gibson JP, Yarrington JT, Loudy DE, Gerbig CG, Hurst GH, and Newberne JW (1990). Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol. Pathol. 18: 225-238.
10.
Graham D. (1989). Neuropathology of vigabatrin. Br. J. Clin. Pharmacol. 27: 43S-45S.
11.
Gram L., Klostekov P., and Dam M. (1985). Gamma-vinyl GABA: A double-blinded placebo-controlled trial in partial epilepsy. Ann. Neurol. 17: 262-266.
12.
Grant SM and Heel RC (1991). Vigabatrin. A review of its pharmacokinetic properties, and therapeutic potential in epilepsy and tardive dyskinesia. Drugs41: 889-926.
13.
Grove J., Palfreyman MG, and Schecter PJ (1983). Cerebrospinal fluid GABA as an index of brain GABA activity. Clin. Neuropharmacol. 6: 223-229.
14.
Hammond EJ and Wilder BJ (1985). Minireview: Gamma-vinyl GABA. Gen. Pharmacol. 16: 441-447.
15.
Hauw J.-J, Trottier S., Boutry J.-M, Sun P., Sazadovitch V., and Duyckaerts C. (1988). The neuropathology of vigabatrin. Br. J. Clin. Pract. 42(suppl.61): 10-13.
16.
John RA, Rimmer EM, Williams J., Cole G., Fowler LJ, and Richens A. (1987). Microvacuolation in rat brains after long term administration of GABA-transaminase inhibitors: Comparison of effects of ethanolamine-o-sulphate and vigabatrin. Biochem. Pharmacol. 36: 1467-1473.
17.
Jung MJ (1980). Design, biochemistry and pharmacology of enzyme-activated irreversible inhibitors of GABA. In: Enzyme Inhibitors, U Brodbeck (ed). Verlag Chemie, Weinheim, pp. 85-95.
18.
Jung M., Lippert B., Metcalf B., Bohlen P., Schecter PJ, and Sjoerdsma A. (1977). γ-vinyl-GABA (4-amino-hex-5-enoic acid). A new selective irreversible inhibitor of GABA-T. Effects on brain GABA metabolism in mice. J. Neurochem. 29: 797-802.
19.
Jung M., Lippert B., Metcalf B., Schechter PJ, and Bohlen P. (1977). The effect of 4-amino-hexynoic acid (γ-acetylenic GABA, γ-ethynyl GABA) a catalytic inhibitor of GABA transaminase, on brain GABA metabolism in vivo. J. Neurochem. 28: 717-723.
20.
Lippert B., Metcalf B., Jung M., and Casara P. (1977). 4-Amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid amino transferase in mammalian brain. Eur . J. Biochem. 74: 441-445.
21.
Lippert B., Metcalf BW, and Resvick RJ (1982). Enzyme-activated irreversible inhibition of rat and mouse brain 4-aminobutyric acid-α-ketoglutarate transaminase by 5-fluoro-4-oxo-pentanoic acid. Biochem. Biophys. Res. Commun. 108: 146-152.
22.
Loiseau P., Pardenberg JP, Pestre M., Guyot M., Schecter PJ, and Tell GP (1986). Double-blind placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy. Epilepsia27: 115-120.
23.
Loshcer W., Jacjel R., and Muller F. (1989). Anticonvulsant and proconvulsant effects of inhibitors of GABA degradation in the amygdala-kindling model. EurJ. Pharmacol. 164: 1-14.
24.
Meldrum M. and Horton R. (1987). Blockade of epileptic responses in the photosensitive baboon, Papio papio, by two irreversible inhibitors of GABA transaminase, γ-acetylenic GABA (4-amino-hex-5-enoic acid) and γ-vinyl GABA (4-amino-hex-5-enoic acid). Psychopharmacology59: 47-50.
25.
Myslobodsky MS, Ackerman RF, and Engel J. Jr. (1979). Effects of γ-vinyl GABA on metrazol-activated, and kindled seizures. Pharmacol. Biochem. Behav. 11: 265-271.
26.
Palyreyman MG, Schecter PJ, Buckett WR, Tell GP, and Koch-Weser J. (1981). The pharmacology of GABA-transaminase inhibitors. Biochem. Pharmacol. 30: 817-824, Errata 2385-2387.
27.
Pedersen B. , Hojgaard K., and Dam M. (1987). Vigabatrin: No microvacuoles in a human brain. Epilepsy Res . 1: 74-76.
28.
Peyster R., Hershey B., Sussman N., Heydorn W., Meyerson L., Yarrington J., and Gibson J. (1993). Use of ex vivo magnetic resonance imaging to detect the onset of vigabatrin-induced microvacuolation in dog brain. Epilepsia (in press).
29.
Rimmer EM and Richens A. (1984). Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet1: 189-190.
30.
Saletu B., Brunberger J., Linzmayer L., Schwartz JJ, Haegle KD, and Schecter PJ (1986). Psychophysiological and psychometric studies after manipulating the GABA system by vigabatrin, a GABA-transaminase inhibitor . Int. J. Psychophysiol. 4: 63-80.
31.
Schecter PJ , Tranier Y., Jung MJ, and Bohlen P. (1977). Audiogenic seizure protection by elevated GABA concentration in mice: Effects of γ-acetylenic GABA and γ-vinyl GABA, two irreversible GABA-T inhibitors. Eur. J. Pharmacol . 45: 319-328.
32.
Schroeder CE , Gibson JP, Yarrington J., Heydorn WE, Sussman NM, and Arezzo JC (1992). Effects of high dose γ-vinyl GABA (vigabatrin) administration on
33.
visual and somatosensory evoked potentials in dogs. Epilepsia33(suppl. 5): S13-S25.
34.
Smithers J. , Lang J., and Okerholm RA (1983). Quantitative analysis of vigabatrin in plasma and urine by reversed-phase high performance liquid chromatography. J. Chromatogr. 341: 232-238.
35.
Snedecor G. and Cochran W. (1980). Statistical Methods, 7th ed. Iowa State University Press, Ames.
36.
Tartara A., Manni R., Galimberti CA, Hardenberg J., Orwin J., and Perucca E. (1986). Vigabatrin in the treatment of epilepsy: A double-blind placebo-controlled study. Epilepsia27: 717-723.
37.
Tassinari CA , Michelucci R., Ambrosetto G., and Salvi F. (1987). Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy . Arch. Neurol. 44: 907-910.
38.
Weiss KL, Schroeder CE, Kastin SJ, Gibson JP, Yarrington JT, Heydorn WE, McBride RG, Sussman NM, and Arezzo JC (1993). MRI monitoring ofvigabatrininduced intramyelinic edema in dogs. Neurology (in press).
